Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at American Society for Gene and Cell Therapy (ASGCT) Annual Meeting May 11-14

On April 27, 2021, Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced that the company will present data from its engEx™ Platform at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held virtually from May 11-14, 2021. Codiak scientists will present four abstracts detailing results from numerous preclinical studies evaluating the potential utility of engineered exosomes in multiple settings, including oncology, infectious disease, gene therapy, and neurology. “In addition to our current clinical programs that are testing engineered exosome therapeutic candidates in immuno-oncology, we see broad opportunity for our platform to create novel, targeted therapeutic approaches in multiple disease areas,” said Douglas E. Williams, PhD, President and Chief Executive Officer of Codiak. “The data to be presented at ASGCT highlights the power of the engEx platform to engineer specific features into exosomes for immune evasion, targeted cell tropism, and potent engagement of previously undruggable pathways, characteristics that serve as the foundation of a new class of medicines.” CODIAK POSTER PRESENTATIONS--MAY 11, 2021; 8:00 A.M. – 10:00 A.M. EDT: exoVACC™: A Novel Exosome-Based Vaccine Platform That Induces Robust, Tunable Cellular and Humoral Immune Responses in Animal Models Abstract number: 721 Session: Immunological Aspects for Gene Therapy and Vaccines Optimization of AAV Loading into Extracellular Vesicles As Method to Avoid Neutralizing Antibodies Abstract number: 320 Session: AAV Vectors – Virology and Vectorology
Login Or Register To Read Full Story